10, Rue Vauquelin
75231 Paris Cedex 05
7 articles with HiFiBiO
HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer
New Nature Genetics publication describes novel high-throughput single-cell ChIP-seq approach to studying heterogeneity of chromatin states within complex biological systems
HiFiBiO Therapeutics and Vikas Sukhatme Join Forces to Discover and Develop Novel Antibody Treatments for Cancer
Victa Biotherapeutics is a new open-innovation joint venture designed to further validate Dr. Sukhatme’s pioneering immuno-oncology research in precision medicine applications
Companies join forces to target different T cell subsets and combat cancer.
Kite and HiFiBiO Therapeutics Announce a Research Collaboration to Develop Technology for the Potential Discovery of Neoantigen-Reactive T Cell Receptors (TCRs) for the Treatment of Cancer
Agreement to develop technology supporting the discovery of neoantigen-reactive T cell receptors (TCRs) for the potential treatment of various cancers, including solid tumors.
Global pharmaceutical leader selects innovative single-B-cell technology to generate breakthrough therapies
HiFiBiO Therapeutics Secures $37.5 Million Series B Financing to Accelerate Pipeline of Novel Antibody Drugs to Treat Cancer and Autoimmune Disorders
Multinational biotherapeutics company announces a new leadership team, expands its global footprint and advances an innovative portfolio of immune modulators for unmet medical needs
HiFiBiO Release: SAS Announces Participation In Next Generation Antibody Therapeutics Session Along With Adimab, F-Star And Innovative Targeting Solutions At Biointernational 2016 In San Francisco, USA